Aller au contenu principal

Introducing ACUVUE® Abiliti™

A powerful approach to managing the progression of myopia in children.

Myopia is a silent epidemic affecting millions of children around the world1—and it is growing fast. It is the greatest eye health threat of the 21st century.2
Research shows that myopia is more than just nearsightedness3. It is a chronic, progressive disease associated with a risk of significant complications later in life3-5 that threatens to take away our most treasured sense: Sight.

Our Commitment

Our commitment to fighting this global health threat.We marvel at the magic of our eyes, yet we are acutely aware there are many who do not fully experience the wonder of this gift1.As one of the world’s most trusted healthcare brands, we (Johnson & Johnson) believe that changing the trajectory of this disease is our responsibility. We’re determined to find ways to slow the progression of myopia in children, potentially reducing the risk of sight-threatening complications in later life. Our ultimate goal is to empower children—including yours—to see their future.And we’re doing it through the Abiliti™ portfolio.

Abiliti™ Approach

The Abiliti™ portfolio is about much more than just vision correction.It’s a comprehensive approach to managing myopia that will include:• Leading with science by continuing to generate new research and evidence• Increasing awareness of myopia as a disease which must be managed• Shaping the future of myopia by changing the trajectory of the disease• Empowering parents, children, and eye care professionals through partnership, education, and advocacy• Offering comprehensive therapies and treatment supportOur purpose is to manage the progression of the disease itself, versus just treating the symptoms. It may sound ambitious, but it’s built on a strong, well-researched foundation. We believe it will help change the way we look at myopia—one child at a time.
Our commitment to fighting this global health threat.We marvel at the magic of our eyes, yet we are acutely aware there are many who do not fully experience the wonder of this gift1.As one of the world’s most trusted healthcare brands, we (Johnson & Johnson) believe that changing the trajectory of this disease is our responsibility. We’re determined to find ways to slow the progression of myopia in children, potentially reducing the risk of sight-threatening complications in later life. Our ultimate goal is to empower children—including yours—to see their future.And we’re doing it through the Abiliti™ portfolio.
Our Commitment

Our Commitment

Our commitment to fighting this global health threat.We marvel at the magic of our eyes, yet we are acutely aware there are many who do not fully experience the wonder of this gift1.As one of the world’s most trusted healthcare brands, we (Johnson & Johnson) believe that changing the trajectory of this disease is our responsibility. We’re determined to find ways to slow the progression of myopia in children, potentially reducing the risk of sight-threatening complications in later life. Our ultimate goal is to empower children—including yours—to see their future.And we’re doing it through the Abiliti™ portfolio.

Abiliti™ Approach

The Abiliti™ portfolio is about much more than just vision correction.It’s a comprehensive approach to managing myopia that will include:• Leading with science by continuing to generate new research and evidence• Increasing awareness of myopia as a disease which must be managed• Shaping the future of myopia by changing the trajectory of the disease• Empowering parents, children, and eye care professionals through partnership, education, and advocacy• Offering comprehensive therapies and treatment supportOur purpose is to manage the progression of the disease itself, versus just treating the symptoms. It may sound ambitious, but it’s built on a strong, well-researched foundation. We believe it will help change the way we look at myopia—one child at a time.
Abiliti™ Approach

Our Commitment

Our commitment to fighting this global health threat.We marvel at the magic of our eyes, yet we are acutely aware there are many who do not fully experience the wonder of this gift1.As one of the world’s most trusted healthcare brands, we (Johnson & Johnson) believe that changing the trajectory of this disease is our responsibility. We’re determined to find ways to slow the progression of myopia in children, potentially reducing the risk of sight-threatening complications in later life. Our ultimate goal is to empower children—including yours—to see their future.And we’re doing it through the Abiliti™ portfolio.

Abiliti™ Approach

The Abiliti™ portfolio is about much more than just vision correction.It’s a comprehensive approach to managing myopia that will include:• Leading with science by continuing to generate new research and evidence• Increasing awareness of myopia as a disease which must be managed• Shaping the future of myopia by changing the trajectory of the disease• Empowering parents, children, and eye care professionals through partnership, education, and advocacy• Offering comprehensive therapies and treatment supportOur purpose is to manage the progression of the disease itself, versus just treating the symptoms. It may sound ambitious, but it’s built on a strong, well-researched foundation. We believe it will help change the way we look at myopia—one child at a time.

Abiliti™ portfolio is a holistic solution built on three main pillars.

see your abiliti™

The Abiliti™ portfolio will have a comprehensive suite of therapies designed to manage the progression of myopia in children. Our goal is clearer vision today, and better eye health in the future.In combination with various forthcoming myopia management products, we offer a digital companion called SeeAbiliti™, a personalized mobile app that provides myopia related lifestyle guidance such as increasing time spent outdoors.Download SeeAbiliti™ App now!Available on:Googleapp store
Abiliti™ Overnight LensesAbiliti™ 1-Day Lenses

master your abiliti™

Your child’s eye care provider will receive unparalleled and personalized support, training, and continuing education in slowing the progression of myopia through the “Master Your Abiliti™” training, administered through our clinical centers of excellence.You can feel confident in knowing that your child is receiving state of the art treatment from highly trained clinicians following the latest practices in myopia management. Additionally, the latest research and evidence on myopia is available to you as well, through the SeeAbiliti™ App.

share your abiliti™

Johnson & Johnson Vision believes that every child deserves the gift of clear sight. That’s why we’re committed to the ongoing Sight For Kids® program with our non-profit partner Lions Clubs International Foundation. And you can be part of this global effort.A 1-for-1 approach: Each annual purchase of an Abiliti™ product will provide a free comprehensive eye exam to a child in need through Sight For Kids®. An eye exam can detect over 270 different medical conditions6, including myopia, and is important in maintaining overall eye health.
Young Asian mother and daughter enjoying the outdoors, glasses-free, which is the goal of Abiliti™ myopia treatments.

With the Abiliti™ portfolio, the power is in your hands.

Together, we can take charge of myopia for your child—and for children around the world. Find an Abiliti™-trained eye care professional near you.

Find a Professional
Eye doctor examining girl with opthalmoscope. Monitoring myopia is an important part of myopia treatment.

REFERENCES

1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmol. 2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.
2. Holy C, Kulkarni K, Brennan NA. Predicting Costs and Disability from the Myopia Epidemic – A Worldwide Economic and Social Model. Investigative ophthalmology & visual science. 2019;60(9):5466-5466.
3. Flitcroft DI The complex interactions of retinal, optical and environmental factors in myopia aetiology. Progress in Retinal and Eye Research. 2012 31(6):622-660.
4. Donovan L, Sankaridurg P, Ho A et al Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.
5. Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.
6. Systemic Conditions with Ocular and Visual Manifestations. American Optometric Association. December 2019.

PP2021ABLM4034
REFERENCES

REFERENCES

1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmol. 2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.
2. Holy C, Kulkarni K, Brennan NA. Predicting Costs and Disability from the Myopia Epidemic – A Worldwide Economic and Social Model. Investigative ophthalmology & visual science. 2019;60(9):5466-5466.
3. Flitcroft DI The complex interactions of retinal, optical and environmental factors in myopia aetiology. Progress in Retinal and Eye Research. 2012 31(6):622-660.
4. Donovan L, Sankaridurg P, Ho A et al Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.
5. Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.
6. Systemic Conditions with Ocular and Visual Manifestations. American Optometric Association. December 2019.

PP2021ABLM4034